Incretin receptor-activating agents, including GLP-1 receptor agonists and dipeptidyl peptidase-IV inhibitors, are currently being clinically used in the treatment of type 2 diabetes mellitus. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.